Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DHX9 | ISIN: DK0061802139 | Ticker-Symbol: 4AJ0
Tradegate
01.11.24
10:12 Uhr
21,840 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
STOXX Europe 600
1-Jahres-Chart
ALK-ABELLO A/S Chart 1 Jahr
5-Tage-Chart
ALK-ABELLO A/S 5-Tage-Chart
RealtimeGeldBriefZeit
21,80022,12011:31
21,74021,94001.11.

Aktuelle News zur ALK-ABELLO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.08.ALK Abello: Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff6
23.08.ALK-Abelló A/S reports Q2 results; raises FY24 outlook5
22.08.ALK Abello: Six-month interim report (Q2) 2024219Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet sales...
► Artikel lesen
22.08.ALK Abello: ALK upgrades its full-year revenue and earnings outlook188ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance and outlook for the remainder of the year. Revenue is...
► Artikel lesen
14.08.ALK Abello: Invitation to the presentation of ALK's results for the first six months (Q2) 2024 on Friday 23 August 20242
21.06.ALK Abello: ALK upgrades its full-year revenue and earnings outlook195ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remainder...
► Artikel lesen
21.06.ALK Abello: ALK provides update on regulatory process for the house dust mite allergy tablet in China164ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application ('BLA') for its house dust mite ('HDM') sublingual allergy immunotherapy tablet...
► Artikel lesen
03.06.ALK Abello: ALK launches new growth strategy and 2028 financial ambitions320ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen ALK's...
► Artikel lesen
03.06.ALK Abello: ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies213At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK presented...
► Artikel lesen
30.05.ALK Abello: ALK's European registration application for ITULAZAX for paediatric indication accepted for review201ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ITULAZAX® (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for review...
► Artikel lesen
29.05.ALK Abello: Listen in on ALK's Capital Markets Day on 4 June 20245
02.05.ALK Abello: Three-month interim report (Q1) 2024 (unaudited)92Company release No. 11/2024 ALK delivers 10% organic revenue growth with operating profit up 41% in Q1 and upgrades outlookThe growth in ALK's overall sales was primarily driven by the European tablet...
► Artikel lesen
02.05.ALK Abello: ALK upgrades its full-year revenue outlook134ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the 2024 full-year financial outlook has been updated. Revenue is now expected to grow by 10-13% in local currencies (previously: 9-12%). The...
► Artikel lesen
08.02.ALK Abello: Annual report 2023: ALK delivers 9% sales growth with profits up 50%40308 February 2024 ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company's 2023 annual report. Following a robust performance in Q4, full-year results were in line with the...
► Artikel lesen
07.02.ALK Abello: ALK and McMaster researchers discover new cell that remembers allergies339Researchers with McMaster University and Denmark-based pharmaceutical company ALK-Abelló A/S have made a ground-breaking discovery: a new cell that remembers allergies. The discovery gives scientists...
► Artikel lesen
05.02.ALK Abello: ALK's 2030 CO2 reduction targets have been approved by SBTi670ALK's near-term carbon reduction targets for scope 1, 2 and 3 have been validated and approved by the Science Based Targets initiative. Today, ALK announces that its near-term carbon reduction targets...
► Artikel lesen
04.01.ALK Abello: ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy339- PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii - The Danish, pharmaceutical company ALK (ALKB:DC...
► Artikel lesen
12.12.23ALK Abello: ALK expands partnership with Torii in Japan376ALK (ALKB:DC / OMX: ALK B / AKBLF) and its Japanese partner Torii Pharmaceutical Co., Ltd. ('Torii') today announced that they have expanded their collaboration and entered into an additional license...
► Artikel lesen
15.11.23ALK Abello: Nine-month interim report (Q3) 2023317ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led by sales of tablets and SCIT. As expected, European tablet sales picked...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1